Prevention of hepatic encephalopathy by administration of rifaximin and lactulose in patients with liver cirrhosis undergoing placement of a transjugular intrahepatic portosystemic shunt (TIPS): a multicentre randomised, double blind, placebo controlled trial (PEARL trial)

Prevention of hepatic encephalopathy by administration of rifaximin and lactulose in patients with liver cirrhosis undergoing placement of a transjugular intrahepatic portosystemic shunt (TIPS): a multicentre randomised, double blind, placebo controlled trial (PEARL trial)

Introduction Cirrhotic patients with portal hypertension can suffer from variceal bleeding or refractory ascites and can benefit from a transjugular intrahepatic portosystemic shunt (TIPS). Post-TIPS hepatic encephalopathy (HE) is a common (20%–54%) and often severe complication. A prophylactic stra...

Full description

Bibliographic Details
Main Authors: M Kramer, K de Wit, J J Schaapman, F Nevens, J Verbeek, S Coenen, F J C Cuperus, E T T L Tjwa, N Mostafavi, M G W Dijkgraaf, O M van Delden, U H W Beuers, M J Coenraad, R B Takkenberg
Format: Article
Language:English
Published: BMJ Publishing Group 2020-11-01
Series:BMJ Open Gastroenterology
Online Access:https://bmjopengastro.bmj.com/content/7/1/e000531.full

Internet

https://bmjopengastro.bmj.com/content/7/1/e000531.full

Similar Items